Physician profile

Jeff Chung

Rheumatology · Emerson, NJ

NPI 1083684088

$9,576.29

in general payments reported to CMS, 2019-2025

50 companies · $2,674 in 2025

The $2,674 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,917.46
Education$149.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $1,411.83 2019-2025 Evenity, Enbrel, Krystexxa
Janssen Biotech, INC. $1,040.35 2019-2025 Tremfya, Simponi Aria
Abbvie INC. $975.30 2019-2025 Rinvoq, Skyrizi, Humira
Novartis Pharmaceuticals Corporation $905.78 2019-2025
Ucb, INC. $643.84 2019-2025 Cimzia, Bimzelx
Lilly USA, LLC $485.53 2019-2024 Taltz
Ani Pharmaceuticals, INC. $461.20 2022-2025 Purified Cortrophin Gel
Pfizer INC. $451.10 2019-2025
Mallinckrodt Hospital Products INC. $358.07 2023-2025 Acthar
E.R. Squibb & Sons, L.L.C. $248.29 2019-2025 Orencia
Radius Health, INC. $236.96 2019-2025 Tymlos
Genzyme Corporation $215.57 2019-2025
Horizon Therapeutics Plc $213.07 2019-2023 Krystexxa
Glaxosmithkline, LLC. $196.07 2019-2025 Benlysta, Trelegy Ellipta, Arexvy
Genentech USA, INC. $169.12 2019-2023 Actemra
Show all 50 companies
CompanyGeneral paymentsYearsTop products
Sobi, INC $133.28 2019-2024
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $114.06 2019-2022
Fresenius Kabi USA, LLC $97.48 2023-2025 Idacio
Celgene Corporation $90.19 2019
Aurinia Pharma U.S., INC. $87.41 2024-2025 Lupkynis
Depuy Synthes Sales INC. $87.17 2019-2025 Orthovisc, Monovisc
Astrazeneca Pharmaceuticals LP $78.78 2022-2025
Ferring Pharmaceuticals INC. $77.00 2019-2025 Euflexxa
Medtronic, INC. $76.27 2023 Minimed 780g
Takeda Pharmaceuticals U.S.A., INC. $73.16 2019-2025 Entyvio
Boehringer Ingelheim Pharmaceuticals, INC. $56.97 2023-2024 Cyltezo
Mallinckrodt Enterprises LLC $42.48 2019
Merck Sharp & Dohme LLC $41.01 2020-2024 Lagevrio, Belsomra
Novo Nordisk INC $40.78 2025
Madrigal Pharmaceuticals $39.80 2025 Rezdiffra
Biocon Biologics INC $36.28 2024 Hulio
Sandoz INC. $33.18 2023-2024 Hyrimoz
Zyla Life Sciences, INC. $28.97 2019-2020
Shire North American Group INC $28.69 2019
Mylan Institutional INC. $27.28 2023 Hulio, Fulphila
Qol Medical, LLC $26.02 2025 Sucraid
Arbor Pharmaceuticals, INC. $25.01 2019
Ironwood Pharmaceuticals, INC $23.58 2019-2020
Blueprint Medicines Corporation $21.24 2024 Ayvakit
Hikma Pharmaceuticals USA $21.00 2022
Appliedvr INC $20.02 2025 Relievrx
Insulet Corporation $18.24 2025 Omnipod
Corcept Therapeutics $17.97 2025 Korlym
Avanos Medical $15.71 2022
Scilex Pharmaceuticals INC. $15.64 2024
Phathom Pharmaceuticals, INC. $15.10 2024 Voquezna
Kiniksa Pharmaceuticals, LTD. $14.27 2022
Alexion Pharmaceuticals, INC. $13.72 2024 Strensiq
Dova Pharmaceuticals $13.65 2019
Medexus Pharma, INC. $12.80 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jeff Chung

$9,576.29

in general payments reported 2019-2025

Years
2019-2025
Top company
Amgen INC.
Context
The $2,674 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).

https://glasscript.com/doctor/4084/jeff-chung

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.